详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Immunotherapy for NSCLC with oncogenic driver variants

108| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Sichuan Univ, Thorac Oncol Ward, Canc Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China [3]Mayo Clin, Div Hematol & Med Oncol, Jacksonville, FL USA [4]Army Med Univ, Daping Hosp, Dept Resp Med, Chongqing, Peoples R China [5]Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, State Key Lab Biotherapy, Chengdu, Peoples R China [6]Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China [7]Heidelberg Univ, German Canc Res Ctr Deutsch Krebsforschungszentrum, Div Pathogenesis Virus Associated Tumors, Heidelberg, Germany

出处：

DOI：

ISSN：

关键词： oncogenic driver variants tumor immune microenvironment lung cancer targeted therapy resistance immune checkpoint inhibitors

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2020]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.5 最新[2023版] 4 最新五年平均 6.244 出版当年[2020版] 6.264 出版当年五年平均 4.848 出版前一年[2019版] 5.738 出版后一年[2021版]

第一作者：

第一作者单位： [1]Sichuan Univ, Thorac Oncol Ward, Canc Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors [2]Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer [3]Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [4]中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版） [5]Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model. [6]The efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer [7]Immune Checkpoint Inhibitors Related to Cardiotoxicity [8]Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence [9]Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations [10]中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）